AzTrials
AzTrials

Healthy AgeingNCT04641429

Neuroplasticity: The Effects of Exercise Training on Cognitive and Affective Functioning of Older People

A study testing Qigong exercise and Stretching exercise in people with Healthy Ageing, run by The University of Hong Kong at 1 site in Hong Kong.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This study investigates the effects of exercise on older people's cognitive and affective functions, and the possible underlying neurobiological pathways. Read more about this study

Who is it for?
Ages 50 to 70 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Ageing
What is being tested?
Qigong exercise and Stretching exercise
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteHong Kong
Study dates
2 Oct 2019to Oct 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 50 to 70 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • At least finished primary school;
  • Have normal or corrected-to-normal vision and hearing;
  • Ability to do exercise;
  • Right-hand dominance;
  • Normal cognitive ability as assessed by the Montreal Cognitive Assessment Hong Kong version (HK-MoCA).

Who cannot join

  • Abmormal anxiety or depression mood as measured by the Hospital Anxiety and Depression Scale;
  • Current diagnosis or history of neurological or psychological conditions, such as substance abuse, psychotic disorders, or affective disorders;
  • Current diagnosis or history of substance/alcohol abuse;
  • Contraindications for MRI scanning (e.g. implanted metal);
  • People who regularly practice any qigong, Tai Chi or similar exercise or meditation within 6 months before study;
  • People who regularly practice moderate to high intensity physical exercise within 6 months before study. The operational definition of 'regular practice' is three times a week or more, at least 30 mins per time for at least 3 months.

Trial locations and contacts

1 site in 1 country.

Tatia Lee, PhD contact

852-39178394

tmclee@hku.hk

Hong Kong1 site, 1 recruiting
  • The University of Hong Kong

    Hong Kong

    Tatia Lee, PhD, 852-39178394, tmclee@hku.hk

    Tatia Lee, PhD

    Recruiting

Other trials in Hong Kong

About this study

This study investigates the effects of exercise on older people's cognitive and affective functions, and the possible underlying neurobiological pathways.

Read the detailed description

Population aging is accelerating. The socioeconomic burden associated with an aging population calls for timely action for promoting brain health. The human brain has the capacity for plastic reorganization through learning and experience. Physical activity could induce plasticity and is important in the prevention of functional decline and increased survival. In this study, the effects of Qigong and stretching exercise on affective and cognitive function among the healthy elderly are investigated. This study is proposed to invite 200 participants (100 in each intervention condition). The investigators acquire data from questionnaires, assessments, neurocognitive tests, magnetic resonance imaging and blood samples at baseline (before the intervention) and post-intervention.

Conditions
Healthy Ageing
Being tested
Qigong exercise, Stretching exercise

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Qigong exerciseBehavioural

    Participants in the experimental group receive 12-week group-based Qigong exercise training.

  • Stretching exerciseBehavioural

    Participants in the control group receive 12-week group-based stretching exercise training.

Study groups in NCT04641429
Study groupRoleWhat they receive
QigongExperimentalParticipants in the experimental group receive Qigong exercise training.
Receives: Behavioral: Qigong exercise
stretchingActive comparatorParticipants in the control group receive stretching exercise training.
Receives: Behavioral: Stretching exercise

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean change from Baseline in cognitive processing speed scores on the Symbol Digit Modalities Test at 12 Weeks

    Changes of cognitive processing speed scores are measured by the Symbol Digit Modalities Test from baseline to end of intervention at 12 Weeks. Scores on the Symbol Digit Modalities Test range from 0-90, with a higher score indicating better performance.

    Measured: from baseline to end of intervention at 12 weeks

  2. Mean change from Baseline in sustained attention scores on the Continuous Performance Test at 12 Weeks

    Changes of sustained attention scores are measured by the Continuous Performance Test from baseline to end of intervention at 12 weeks. The accuracy scores on the Continuous Performance Test range from 0-100%, with a higher score indicating better performance.

    Measured: from baseline to end of intervention at 12 weeks

  3. Mean change from Baseline in working memory scores on the Digit Span-Backward Test at 12 Weeks

    Changes of working memory scores are measured by the Digit Span Backward Test from baseline to end of intervention at 12 weeks. Scores on the Digit Span-Backward test range from 2-13, with a higher score indicating better performance.

    Measured: from baseline to end of intervention at 12 weeks

  4. Mean change from Baseline in language scores on the Rapid Naming Test at 12 Weeks

    Changes of language scores are measured by the Rapid Naming Test from baseline to end of intervention at 12 weeks. Scores on the Rapid Naming Test range from 0-36, with a higher score indicating better performance.

    Measured: from baseline to end of intervention at 12 weeks

  5. Mean change from Baseline in trait affect scores on the Chinese Affect Scale at 12 Weeks

    Changes of trait positive affect and negative affect are measured by the Chinese Affect Scale from baseline to end of intervention at 12 weeks. Positive and negative affect scores on Chinese Affect Scale both range from 10-50, with a higher score indicating higher positive/negative affect.

    Measured: from baseline to end of intervention at 12 weeks

  6. Mean change from Baseline in affective processing by the Emotion Processing Task at 12 weeks

    Changes of affective stimuli processing are measured by the Emotion Processing Task from baseline to end of intervention at 12 weeks.

    Measured: from baseline to end of intervention at 12 weeks

  7. Mean change from Baseline in blood levels of cortisol at 12 Weeks

    Changes of blood biomarker levels of cortisol are measured from baseline to end of intervention at 12 weeks.

    Measured: from baseline to end of intervention at 12 weeks

  8. Mean change from Baseline in blood levels of interleukin-6 at 12 Weeks

    Changes of blood biomarker levels of interleukin-6 are measured from baseline to end of intervention at 12 weeks.

    Measured: from baseline to end of intervention at 12 weeks

  9. Mean change from Baseline in blood levels of brain-derived neurotrophic factor at 12 Weeks

    Changes of blood biomarker levels of brain-derived neurotrophic factor are measured from baseline to end of intervention at 12 weeks.

    Measured: from baseline to end of intervention at 12 weeks

  10. Mean change from Baseline in telomerase activity at 12 Weeks

    Changes of blood measurement of telomerase activity are measured from baseline to end of intervention at 12 weeks.

    Measured: from baseline to end of intervention at 12 weeks

  11. Mean change from Baseline in brain structure by magnetic resonance imaging at 12 Weeks

    Changes of brain structure are measured by T1-weighted magnetic resonance imaging from baseline to end of intervention at 12 Weeks.

    Measured: from baseline to end of intervention at 12 weeks

  12. Mean change from Baseline in brain function by functional magnetic resonance imaging at 12 Weeks

    Changes of brain function are measured by functional magnetic resonance imaging from baseline to end of intervention at 12 Weeks.

    Measured: from baseline to end of intervention at 12 weeks

Secondary outcomes (8)
  1. Mean change from Baseline in perceived stress scores on the Perceived Stress Scale at 12 weeks

    Changes of perceived stress scores are measured by the Perceived Stress Scale from baseline to end of intervention at 12 weeks. Scores on the Perceived Stress Scale range from 0-56, with a higher score indicating higher perceived stress.

    Measured: from baseline to end of intervention at 12 weeks

  2. Mean change from Baseline in insomnia severity scores on the Insomnia Severity Index at 12 weeks

    Changes of insomnia severity scores are measured by the Insomnia Severity Index from baseline to end of intervention at 12 weeks. Scores on the Insomnia Severity Index range from 0-28, with a higher score indicating more severe insomnia.

    Measured: from baseline to end of intervention at 12 weeks

  3. Mean change from Baseline in quality of sleep on the Pittsburg Seep Quality Index at 12 weeks

    Changes of quality of sleep scores are measured by the Pittsburg Seep Quality Index from baseline to end of intervention at 12 weeks. Scores on the Pittsburg Seep Quality Index range from 0-21, with a higher score indicating more severe sleeping difficulty.

    Measured: from baseline to end of intervention at 12 weeks

  4. Mean change from Baseline in depression and anxiety scores on the Hospital Anxiety and Depression Scale at 12 weeks

    Changes of depression and anxiety scores are measured by the Hospital Anxiety and Depression Scale from baseline to end of intervention at 12 weeks. Anxiety and Depression scores on the Hospital Anxiety and Depression Scale both range from 0-21, with a higher score indicating more severe anxiety/depression mood.

    Measured: from baseline to end of intervention at 12 weeks

  5. Mean change from Baseline in perceived loneliness scores on the UCLA Loneliness Scale at 12 weeks

    Changes of perceived loneliness scores are measured by the UCLA Loneliness Scale from baseline to end of intervention at 12 weeks. The scores on the UCLA Loneliness Scale range from 20-80, with a higher score indicating greater perceived loneliness.

    Measured: from baseline to end of intervention at 12 weeks

  6. Mean change from Baseline in quality of life scores on the WHO Quality of Life-BREF scale at 12 weeks

    Changes of quality of life scores are measured by the WHO Quality of Life-BREF scale from baseline to end of intervention at 12 weeks. The scores on the WHO Quality of Life-BREF scale range from 26-130, with a higher score indicating higher quality of life.

    Measured: from baseline to end of intervention at 12 weeks

  7. Mean change from Baseline in emotion reactivity scores on the Emotion Reactivity Scale at 12 weeks

    Changes of emotion reactivity scores are measured by the Emotion Reactivity Scale from baseline to end of intervention at 12 weeks. The scores on the Emotion Reactivity Scale range from 0-84, with a higher score indicating greater emotional reactivity.

    Measured: from baseline to end of intervention at 12 weeks

  8. Mean change from Baseline in somatization scores on the somatization subscale of Symptom Check-List-90 at 12 weeks

    Changes of somatization scores are measured by the somatization subscale of Symptom Check-List-90 from baseline to end of intervention at 12 weeks. Scores on the somatization subscale of Symptom Check-List-90 range from 0-48, with a higher score indicating greater somatization.

    Measured: from baseline to end of intervention at 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Nov 2020
  2. Study start2 Oct 2019
  3. Primary completionOct 2021 (estimated)
  4. Study completionOct 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
In this intervention study, each participant is allocated to either the Qigong or stretching exercise training group in a pseudo-randomized order based on the recruitment orders and their availability.
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04641429
Sponsor's protocol ID
UW 19-005
Status last verified
Nov 2020
First submitted
12 Nov 2020
Last updated
23 Nov 2020
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Qi D, Wong NML, Shao R, Man ISC, Wong CHY, Yuen LP, Chan CCH, Lee TMC. Qigong exercise enhances cognitive functions in the elderly via an interleukin-6-hippocampus pathway: A randomized active-controlled trial. Brain Behav Immun. 2021 Jul;95:381-390. doi: 10.1016/j.bbi.2021.04.011. Epub 2021 Apr 17.

    PubMed 33872709

Questions about this trial

What is this clinical trial studying?

A study testing Qigong exercise and Stretching exercise in people with Healthy Ageing, run by The University of Hong Kong at 1 site in Hong Kong.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 23 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Tatia Lee, PhD (852-39178394, tmclee@hku.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean change from Baseline in cognitive processing speed scores on the Symbol Digit Modalities Test at 12 Weeks (time frame: from baseline to end of intervention at 12 weeks). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04641429, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Nov 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in